SCHEMBL1573576

SCHEMBL1573576

CS(=O)(=O)OCCN1CCN(CCOS(C)(=O)=O)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.50
TSHR P16473 2/20 0.50
ALOX15 P16050 2/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MMP9 P14780 1/20 0.50
NPC1 O15118 1/20 0.39
LTA4H P09960 1/20 0.34
DRD3 P35462 3/20 0.33
DRD2 P14416 2/20 0.33
HRH3 Q9Y5N1 2/20 0.33
KCNH2 Q12809 2/20 0.32
KCNA5 P22460 3/20 0.31
HSD11B1 P28845 1/20 0.31
SLC29A1 Q99808 1/20 0.31
KCNJ1 P48048 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10868169 0.94 ALDH1A1 (0.44) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL13187873 0.92 ALDH1A1 (0.43) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL13187900 0.92 ALDH1A1 (0.43) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL10554729 0.92 KDM4E (0.54) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL2078423 0.91 KDM4E (0.46) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL8223233 0.90 ALDH1A1 (0.41) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL2077149 0.89 KDM4E (0.44) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL2075399 0.89 KDM4E (0.44) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL13187885 0.88 CA12 (0.44) USP2TSHRALOX15KDM4EALDH1A1
SCHEMBL13187884 0.87 KDM4E (0.39) USP2TSHRALOX15KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9120819-B2 FGF-receptor agonist dimeric compounds SANOFI (FR) 2015-09-01 US disclosed
EP-2018165-B1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI AVENTIS (FR) 2011-04-13 EP disclosed
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2009-03-12 US disclosed
EP-2018165-A1 FGF-PECEPTOR AGONIST DIMERIC COMPOUNDS Sanofi-Aventis (FR) 2009-01-28 EP disclosed
WO-2007080325-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS SANOFI-AVENTIS (FR) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069368-A1 FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS FGF2, FGFR1, FGF1 USP2 4003/4885TSHR 156/4885ALOX15 3658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.